NCT06679322Not yet recruitingPhase 2
The Androtriol Injection for the Treatment of Acute Ischemic Stroke
A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IIb Clinical Trial of Androtriol Injection for the Treatment of Acute Ischemic Stroke
Source: ClinicalTrials.gov · Last updated 7 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a prospective, multicenter, randomized, double-blind, placebo-controlled, phase IIb clinical trial of Androtriol injection for the treatment of acute ischemic stroke. The goal of this trial is to explore the efficacy and safety of different doses of Androtriol injection in patients with acute ischemic stroke (AIS) who received vascular recanalization treatment within 24 hours of symptom onset. Participants will receive a low-dose Androtriol injection (100 mg BID), a high-dose Androtriol injection (300 mg BID), or a placebo intravenously within 24 hours of stroke onset. They will be treated twice daily (every 12 hours) for 7 days, with a total of 14 doses over the course of the study. Each infusion will last approximately 30±5 minutes.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 29 Oct 2024
- Start date
- 31 Oct 2024
- Primary completion date
- 30 Sept 2025
- Lead sponsor
- Beijing Tiantan Hospital
- Diseases
- Stroke
- NCT number
- NCT06679322
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 300
- From 31 Oct 2024 to the primary completion date, 30 Sept 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Severe injury or surgery history within 3 months of onset;
- Have received\>1 dose of neuroprotective drugs after this onset, such as edaravone, edaravone dexborneol injection, ginkgo lactone, ginkgo diterpene glucamine，etc;
- Allergy to the investigational drug (either the active ingredient androtriol or the excipient hydroxypropyl beta-cyclodextrin) or similar chemical structure drugs;
Other illness
- Intracranial hemorrhagic diseases, including hemorrhagic stroke, epidural hematoma, intracranial hematoma, ventricular hemorrhage, subarachnoid hemorrhage, etc.;
- Severe disorders of consciousness: NIHSS 1a≥2 points;
- Severe hypertension: systolic blood pressure ≥185mmHg or diastolic blood pressure ≥110mmHg after medication control;
- Cardiovascular diseases, such as complete atrioventricular block, history of congestive heart failure (CHF), or heart function classification≥NYHA Class III;
- History of epilepsy or epilepsy-like symptoms during stroke or severe psychiatric disorders, intellectual disability, or dementia;
- History of intracranial hemorrhage;
Lab values
- History of severe kidney disease (such as dialysis), or eGFR \<45 mL/min/1.73m²;
- History of severe liver disease, or ALT, AST levels more than 3 times of the upper limit of normal, or bilirubin more than 3 times of the upper limit of normal;
Other
- Large infarct core (ASPECTS \<6, or\>1/3 of MCA territory involved, as evidenced by CT or MRI);
- Critically ill patients with an expected lifespan≤90 days;
- Pregnant or breastfeeding;
- Participation in other clinical trials within 3 months of onset;
- Unsuitable for participating in this study judged by investigator.
Who the study is looking for
- Age 18- 80 years, male or female；
- mRS score ≤1 prior to this onset;
- Planning to receive or have received intravascular recanalization therapy at our center within 24h of onset;
- To complete the first administration of the investigational medication within 24h of onset;
- NIHSS（National Institutes of Health Stroke Scale）score≥6 prior to intravascular recanalization;
- Informed consent.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.